-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68

Benzinga·03/26/2026 15:35:48
Listen to the news
Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $64 to $68.